What We Offer
Our Products
ViraDx™
Product Overview
ViraDx™ SARS-CoV-2/Flu A+B Rapid Antigen Point-of-Care Test is a lateral flow immunoassay intended for in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, influenza A and influenza B directly from anterior nasal or nasopharyngeal swab specimens obtained from patients who are suspected of COVID-19 by their healthcare provider, within the first five days of onset of symptoms.
  • 1 sample - 3 results
  • SARS-CoV-2/Flu A+B Rapid POC Combo Antigen Test
  • Simultaneous testing for acute respiratory infections caused by COVID-19, Flu A, Flu B
  • Lateral flow immunoassay
  • Covid-19: Sensitivity 93.8%; Specificity 100%
  • Flu A: Sensitivity 92.2%; Specificity 94.2%
  • Flu B: Sensitivity 90.0%; Specificity 94.3%
  • Nasal or nasopharyngeal swab samples
  • Delivers results within 15 minutes
  • No equipment necessary
  • CLIA Waived Test
VISIT WEBSITE

Quick Links

RCS Healthcare: Our Vision
To be the leading global procurement company for the healthcare community.
LEARN MORE